Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Survivorship Care Plans in Cancer: A Meta-Analysis and Systematic Review of Care Plan Outcomes.

Hill RE, Wakefield CE, Cohn RJ, Fardell JE, Brierley ME, Kothe E, Jacobsen PB, Hetherington K, Mercieca-Bebber R.

Oncologist. 2020 Feb;25(2):e351-e372. doi: 10.1634/theoncologist.2019-0184. Epub 2019 Oct 25. Review.

2.

Survivorship Care Plans in Cancer: A Meta-Analysis and Systematic Review of Care Plan Outcomes.

Hill RE, Wakefield CE, Cohn RJ, Fardell JE, Brierley ME, Kothe E, Jacobsen PB, Hetherington K, Mercieca-Bebber R.

Oncologist. 2019 Oct 25. pii: theoncologist.2019-0184. doi: 10.1634/theoncologist.2019-0184. [Epub ahead of print] Review.

3.

U.K. utility weights for the EORTC QLU-C10D.

Norman R, Mercieca-Bebber R, Rowen D, Brazier JE, Cella D, Pickard AS, Street DJ, Viney R, Revicki D, King MT; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and the MAUCa Consortium.

Health Econ. 2019 Dec;28(12):1385-1401. doi: 10.1002/hec.3950. Epub 2019 Sep 3.

PMID:
31482619
4.

The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.

Mercieca-Bebber R, Costa DS, Norman R, Janda M, Smith DP, Grimison P, Gamper EM, King MT.

Med J Aust. 2019 Jun;210(11):499-506. doi: 10.5694/mja2.50207. Epub 2019 Jun 2.

PMID:
31155722
5.

Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials.

Kyte D, Retzer A, Ahmed K, Keeley T, Armes J, Brown JM, Calman L, Gavin A, Glaser AW, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Efficace F, Mercieca-Bebber R, King MT, Turner G, Calvert M.

J Natl Cancer Inst. 2019 Nov 1;111(11):1170-1178. doi: 10.1093/jnci/djz038.

6.

Patient, client, consumer, survivor or other alternatives? A scoping review of preferred terms for labelling individuals who access healthcare across settings.

Costa DSJ, Mercieca-Bebber R, Tesson S, Seidler Z, Lopez AL.

BMJ Open. 2019 Mar 7;9(3):e025166. doi: 10.1136/bmjopen-2018-025166.

7.

Trials with proxy-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR).

Mercieca-Bebber R, Williams D, Tait MA, Rutherford C, Busija L, Roberts N, Wilson M, Shunmuga Sundaram C, Roydhouse J; International Society for Quality of Life Research (ISOQOL) Australia and New Zealand Special Interest Group.

Qual Life Res. 2019 Apr;28(4):955-962. doi: 10.1007/s11136-018-2080-4. Epub 2018 Dec 15.

PMID:
30554370
8.

The importance of patient-reported outcomes in clinical trials and strategies for future optimization.

Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M.

Patient Relat Outcome Meas. 2018 Nov 1;9:353-367. doi: 10.2147/PROM.S156279. eCollection 2018. Review.

9.

A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer.

Wilson MK, Mercieca-Bebber R, Friedlander M.

J Gynecol Oncol. 2018 Sep;29(5):e81. doi: 10.3802/jgo.2018.29.e81. Epub 2018 Jun 9. Review.

10.

Correction to: Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR).

Mercieca-Bebber R, Williams D, Tait MA, Roydhouse J, Busija L, Sundaram CS, Wilson M, Langford A, Rutherford C, Roberts N, King M, Vodicka E, Devine B; International Society for Quality of Life Research (ISOQOL).

Qual Life Res. 2018 Oct;27(10):2593. doi: 10.1007/s11136-018-1934-0.

PMID:
30014457
11.

Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR).

Mercieca-Bebber R, Williams D, Tait MA, Roydhouse J, Busija L, Sundaram CS, Wilson M, Langford A, Rutherford C, Roberts N, King M, Vodicka E, Devine B; International Society for Quality of Life Research (ISOQOL).

Qual Life Res. 2018 Oct;27(10):2581-2591. doi: 10.1007/s11136-018-1921-5. Epub 2018 Jun 18. Erratum in: Qual Life Res. 2018 Jul 16;:.

PMID:
29915979
12.

The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training.

Mercieca-Bebber R, Calvert M, Kyte D, Stockler M, King MT.

Contemp Clin Trials Commun. 2017 Nov 23;9:23-32. doi: 10.1016/j.conctc.2017.11.009. eCollection 2018 Mar.

13.

Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol.

Retzer A, Keeley T, Ahmed K, Armes J, Brown JM, Calman L, Copland C, Efficace F, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M, Kyte D.

BMJ Open. 2018 Feb 3;8(2):e017282. doi: 10.1136/bmjopen-2017-017282.

14.

Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.

Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT; the SPIRIT-PRO Group, Hunn A, Bottomley A, Regnault A, Chan AW, Ells C, O'Connor D, Revicki D, Patrick D, Altman D, Basch E, Velikova G, Price G, Draper H, Blazeby J, Scott J, Coast J, Norquist J, Brown J, Haywood K, Johnson LL, Campbell L, Frank L, von Hildebrand M, Brundage M, Palmer M, Kluetz P, Stephens R, Golub RM, Mitchell S, Groves T.

JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.

15.

Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.

King MT, Viney R, Simon Pickard A, Rowen D, Aaronson NK, Brazier JE, Cella D, Costa DSJ, Fayers PM, Kemmler G, McTaggart-Cowen H, Mercieca-Bebber R, Peacock S, Street DJ, Young TA, Norman R; MAUCa Consortium.

Pharmacoeconomics. 2018 Feb;36(2):225-238. doi: 10.1007/s40273-017-0582-5.

16.

A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data.

Palmer MJ, Mercieca-Bebber R, King M, Calvert M, Richardson H, Brundage M.

Clin Trials. 2018 Feb;15(1):95-106. doi: 10.1177/1740774517741113. Epub 2017 Nov 10.

PMID:
29124956
17.

Treatment decision-making in ductal carcinoma in situ: A mixed methods systematic review of women's experiences and information needs.

Rutherford C, Mercieca-Bebber R, Butow P, Wu JL, King MT.

Patient Educ Couns. 2017 Sep;100(9):1654-1666. doi: 10.1016/j.pec.2017.04.009. Epub 2017 Apr 15. Review.

PMID:
28442156
18.

Erratum to: The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols.

Mercieca-Bebber R, Friedlander M, Kok PS, Calvert M, Kyte D, Stockler M, King MT.

Qual Life Res. 2017 Aug;26(8):2249-2250. doi: 10.1007/s11136-017-1578-5. No abstract available.

PMID:
28434060
19.

What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?

Mercieca-Bebber R, King MT, Boxer MM, Spillane A, Winters ZE, Butow PN, McPherson J, Rutherford C.

Breast Cancer. 2017 Sep;24(5):720-729. doi: 10.1007/s12282-017-0765-0. Epub 2017 Feb 28.

PMID:
28247220
20.

Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension.

Mercieca-Bebber R, Rouette J, Calvert M, King MT, McLeod L, Holch P, Palmer MJ, Brundage M; International Society for Quality of Life Research (ISOQOL) Best Practice for PROs—Reporting Taskforce.

Qual Life Res. 2017 Jun;26(6):1427-1437. doi: 10.1007/s11136-017-1508-6. Epub 2017 Feb 7.

PMID:
28168602
21.

A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice.

Mercieca-Bebber R, Friedlander M, Calvert M, Stockler M, Kyte D, Kok PS, King MT.

J Patient Rep Outcomes. 2017;1(1):5. doi: 10.1186/s41687-017-0008-3. Epub 2017 Oct 4.

22.

Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol.

Ahmed K, Kyte D, Keeley T, Efficace F, Armes J, Brown JM, Calman L, Copland C, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor R, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M.

BMJ Open. 2016 Sep 21;6(9):e012863. doi: 10.1136/bmjopen-2016-012863.

23.

Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time.

Mercieca-Bebber RL, Price MA, Bell ML, King MT, Webb PM, Butow PN; Australian Ovarian Cancer Study (AOCS) Group.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e381-e388. doi: 10.1111/ajco.12580. Epub 2016 Aug 30.

PMID:
27573704
24.

Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review.

Mercieca-Bebber R, Palmer MJ, Brundage M, Calvert M, Stockler MR, King MT.

BMJ Open. 2016 Jun 15;6(6):e010938. doi: 10.1136/bmjopen-2015-010938. Review.

25.

The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols.

Mercieca-Bebber R, Friedlander M, Kok PS, Calvert M, Kyte D, Stockler M, King MT.

Qual Life Res. 2016 Oct;25(10):2457-2465. doi: 10.1007/s11136-016-1339-x. Epub 2016 Jun 13. Review. Erratum in: Qual Life Res. 2017 Apr 22;:.

PMID:
27294435
26.

Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.

Friedlander M, Mercieca-Bebber RL, King MT.

Ann Oncol. 2016 Apr;27 Suppl 1:i66-i71. doi: 10.1093/annonc/mdw080.

27.

Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation.

Mercieca-Bebber RL, Perreca A, King M, Macann A, Whale K, Soldati S, Jacobs M, Efficace F.

Eur J Cancer. 2016 Mar;56:144-161. doi: 10.1016/j.ejca.2015.12.025. Epub 2016 Feb 4. Review.

PMID:
26851406
28.

Mode of administration does not cause bias in patient-reported outcome results: a meta-analysis.

Rutherford C, Costa D, Mercieca-Bebber R, Rice H, Gabb L, King M.

Qual Life Res. 2016 Mar;25(3):559-74. doi: 10.1007/s11136-015-1110-8. Epub 2015 Sep 3. Review.

PMID:
26334842
29.

International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies.

Kyte D, Reeve BB, Efficace F, Haywood K, Mercieca-Bebber R, King MT, Norquist JM, Lenderking WR, Snyder C, Ring L, Velikova G, Calvert M.

Qual Life Res. 2016 Feb;25(2):359-362. doi: 10.1007/s11136-015-1099-z. Epub 2015 Aug 15.

30.

Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers.

Calvert M, Kyte D, Duffy H, Gheorghe A, Mercieca-Bebber R, Ives J, Draper H, Brundage M, Blazeby J, King M.

PLoS One. 2014 Oct 15;9(10):e110216. doi: 10.1371/journal.pone.0110216. eCollection 2014.

31.

Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols.

Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M, Draper H, Ives J, Brundage M, Blazeby J, Calvert M.

PLoS One. 2014 Oct 15;9(10):e110229. doi: 10.1371/journal.pone.0110229. eCollection 2014.

32.

Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.

King MT, Stockler MR, Butow P, O'Connell R, Voysey M, Oza AM, Gillies K, Donovan HS, Mercieca-Bebber R, Martyn J, Sjoquist K, Friedlander ML.

Int J Gynecol Cancer. 2014 Jun;24(5):865-73. doi: 10.1097/IGC.0000000000000167.

PMID:
24844220

Supplemental Content

Loading ...
Support Center